Basel Medical Group (NASDAQ:BMGL) vs. Sera Prognostics (NASDAQ:SERA) Head-To-Head Analysis

Sera Prognostics (NASDAQ:SERA) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Earnings and Valuation

This table compares Sera Prognostics and Basel Medical Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80,000.00	1,032.81	-$31.93 million	($0.68)	-3.10
Basel Medical Group	$8.90 million	1.25	-$9.50 million	N/A	N/A

Basel Medical Group has higher revenue and earnings than Sera Prognostics.

Analyst Recommendations

This is a summary of recent recommendations for Sera Prognostics and Basel Medical Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1	0	0	1	2.50
Basel Medical Group	1	0	0	0	1.00

Sera Prognostics currently has a consensus price target of $5.00, indicating a potential upside of 136.85%. Given Sera Prognostics’ stronger consensus rating and higher possible upside, research analysts plainly believe Sera Prognostics is more favorable than Basel Medical Group.

Institutional and Insider Ownership

54.6% of Sera Prognostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Sera Prognostics and Basel Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-39,417.29%	-37.50%	-29.02%
Basel Medical Group	N/A	N/A	N/A

Summary

Sera Prognostics beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

About Basel Medical Group

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.